Connect with us

IT Industry

iBio Inks 3D Bioprinting Agreement

GlobeNewswire

Published

on

Reading Time: 2 minutes

NEW YORK, Aug. 19, 2019 (GLOBE NEWSWIRE) — iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a Master Services Agreement (“MSA”) with Lung Biotechnology PBC, a subsidiary of United Therapeutics Corporation (NASDAQ:UTHR), to produce recombinant human collagen (“rhCollagen”)-based bioink for 3D bioprinted organ transplants. iBio will collaborate with Lung Biotechnology PBC to scale-up production of rhCollagen in tobacco plants using iBio’s FastPharming™ System.

Under the MSA, the initial work to be performed by iBio involves the development of a scalable purification process for rhCollagen tailored to the biofabrication of lung scaffolds that United Therapeutics licensed from CollPlant Biotechnologies Inc. (NASDAQ:CLGN), as well as cGMP supply of the material for clinical trials. Anticipating the need for commercial quantities of rhCollagen-based bioinks, iBio envisions additional projects focused upon process optimization and capacity expansion, the latter of which will employ iBio’s Factory Solutions capabilities.

“We’re pleased to have been selected by United Therapeutics to help in the mission to fundamentally change access to vital organ transplants for patients,” said Tom Isett, a member of iBio’s Board of Directors. “The FastPharming System is ideally suited to the production of bioinks, maturogens, and other biologics for use in 3D bioprinting, so iBio will remain committed to delivering its safety, quality, performance and cost advantages to pioneers like United Therapeutics in the transformational, cutting-edge biofabrication industry.”

Robert B. Kay, iBio’s Chairman and CEO commented that, “Recent scientific breakthroughs in the emerging field of 3D bioprinting have captured headlines worldwide. The decision by United Therapeutics to work with iBio for the production of rhCollagen bioinks in our FastPharming System provides yet another opportunity to demonstrate the strength of our platform, which has already been proven in the manufacture of monoclonal antibodies, growth factors, fusion proteins, virus-like particles, and other biologics. We’re looking forward to helping United Therapeutics to successfully address the critical shortage of transplantable lungs and other organs.”  

About iBio, Inc.
iBio is a global leader in plant-based biopharmaceutical contract development and cGMP manufacturing services.  Our wholly-owned subsidiary, iBio CDMO LLC, uses the FastPharming™ System – which combines plant protein expression, automated hydroponics, and glycan engineering technologies – to rapidly deliver gram quantities of high-quality biologics for research or further manufacturing uses from its 120,000 square foot facility in Bryan, Texas. In addition to contract manufacturing, iBio also offers process development, bioanalytical, and fill-finish services, along with Factory Solutions for the design and build of facilities for plant-made monoclonal antibodies, vaccines, bioinks and more. iBio also uses its advanced manufacturing capabilities in the development of its own therapeutic pipeline, including its lead asset, CFB-03 for the treatment of fibrotic diseases. For more information, visit www.ibioinc.com

FORWARD-LOOKING STATEMENTS
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY’S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY’S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY’S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

Contact:

Stephen Kilmer
Investor Relations
(646) 274-3580
skilmer@ibioinc.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

IT Industry

IDEX begins deliveries of its dual-interface sensor to world class electronics manufacturer

GlobeNewswire

Published

on

Reading Time: 1 minute

Oslo, Norway, 15 October 2019: IDEX Biometrics ASA, a leading provider of advanced fingerprint identification and authentication solutions, has received a purchase order and initiated production ramp preparations to fulfill a multi-year order commitment signed with a leading provider of global financial news and IT services, as announced in April this year.

As part of this multimillion-dollar commitment IDEX is supplying its dual-interface sensors to one of the world’s largest electronics manufacturing service companies in order to qualify their manufacturing process; a critical step in any ramp-up process.

Stan Swearingen, CEO of IDEX Biometrics comments: “This is an exciting time for IDEX as we gear up volume production with our partners in what will be a cutting-edge, secure access solution. We now expect a regular flow of purchase orders from this customer and look forward to being an integral part of the rollout of their enhanced biometric security solutions”.

For further information contact:
Stuart Hunt, Head of Investor Relations & Communications
+44 (0)1276 534 632

About IDEX Biometrics
IDEX Biometrics ASA (OSE: IDEX) is the leading provider of fingerprint identification technologies offering simple, secure and personal authentication for all. We help people make payments, prove their identity, gain access to information, unlock devices or gain admittance to buildings with the touch of a finger. We invent, engineer and commercialize these secure, yet incredibly user-friendly solutions. Our total addressable market represents a fast-growing multi-billion-unit opportunity.

For more information, visit www.idexbiometrics.com and follow @IDEXBiometrics

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Continue Reading

IT Industry

Global e∙dentity™ files its third formal USPTO 37CFR1.290 request in six months against Apple AAPL (NASDAQ)

GlobeNewswire

Published

on

Reading Time: 1 minute

WILMINGTON, Del., Oct. 15, 2019 (GLOBE NEWSWIRE) — Global e∙dentity™, founded by Robert Adams, U.S. Navy veteran who along with the most amazing engineers & team, have developed and patented the next generation of identity protocol methods, has now filed its third 37CFR1.290 request with the USPTO within in six months against Apple; the formal third-party review request with the USPTO is in opposition to Apple newest patent application 16/262032 published on September 12, 2019. Adams stated that Global e∙dentity™ had “no choice, and once again, file a new third-party action with the USPTO in response to Apple’s latest published patent application.”  USPTO new third party filing is noted on the Global e·dentity™ website: https://www.globaledentity.com/third-party-review-uspto3/

Global e∙dentity™ was featured on Featured on KRON4 — San Francisco Bay Area’s Local TV www.globaledentity.com/2019/06/22/kron4-apple-intellectual-property-theft-and-patent-violations with regards the first of two third-party actions with the USPTO against Apple.  Adams continued, “We are indeed flattered that Apple has now filed, not one, not two, but now a third patent application based on our already patented technology 10,135,822 Biometric authentication of individuals utilizing characteristics of bone and blood vessel structures and its continuation patents.   Having said that, the key question remains: Why did Apple fail to inform the USPTO they had in their possession per their request, all of our trade secrets and provisional patent as early as March/April 2017 when negotiations started between representatives of Apple and Global e∙dentity?”

Global e·dentity™, is young well-funded tech start-up company with national security applications in mind; providing secure multi-factor biometric and digital identity solutions. For more information, visit www.globaledentity.com. Global e·dentity™ and product are either registered trademarks or trademarks of You are the ID ™ LLC in the United States and/or other countries.

For more information, press only: Sophia Miller  sophiam@globaledentity.com

Continue Reading

IT Industry

Digia Plc will publish its business review January-September 2019 on October 31, 2019

GlobeNewswire

Published

on

Reading Time: 1 minute

Digia Plc
Investor News
15 October 2019 at 09:00 am


Digia Plc will publish its business review January-September 2019 on Thursday 31 October at 8:00 am EET (GMT +2). After the publishing the report is available on: https://digia.com/en/investors/stock-exchange-releases/.

Timo Levoranta, President & CEO, and Kristiina Simola, CFO, will present the financial results in Finnish at an analyst and press conference in Helsinki on Thursday, October 31, 2019 at 11.00 am (EET). The conference will take place at Business Meeting Park in Helsinki (address: Forum, Mannerheimintie 20 B, 6th floor. Entrance from the glass corner of Mannerheimintie and Simonkatu).

The material and presentation for the event will be available from 11 am on October 31, 2019 in the Investors section of the company’s website: www.digia.com/en/investors/reports-and-presentations.

Digia Oyj
Timo Levoranta, CEO


Additional information:

Kristiina Simola, CFO, tel. +358 40 756 3132

Distribution:
Nasdaq Helsinki
Key media
digia.com

Digia is a software and service company that helps its customers renew themselves digitally. There are more than 1,200 of us working at Digia. Our roots are in Finland and we operate with our customers in Finland and abroad. world. We are building a world in which digitalisation makes a difference. Digia net sales were EUR 112.1 million in 2018. The company is listed on Nasdaq Helsinki (DIGIA). digia.com

Continue Reading

Font Resizer

Subscribe to PICANTE via Email

Enter your email address to subscribe to PICANTE and receive notifications of new posts by email.

Follow us on Facebook

Read more from our authors

Follow our Tweets

Trending

Please turn AdBlock off